Table 1 Descriptive patient characteristics
From: Teamwork enables high level of early mobilization in critically ill patients
All admissions (n = 171) | Mobilized n = 139 | Never mobilized n = 32 | p value |
|---|---|---|---|
Agea | 59 ± 17 | 62 ± 17 | 0.36 |
Maleb | 80 (58 %) | 18 (56 %) | 0.99 |
SOFA scorea | 5 ± 3 | 8 ± 5 | 0.01 |
APACHE II scorea | 17 ± 7 | 22 ± 9 | <0.001 |
Predicted mortality (APACHE II) | 29 % | 44 % | 0.017 |
In-hospital mortalityb | 26 (19 %) | 16 (50 %) | <0.001 |
In ICU mortalityb | 11 (8 %) | 13 (41 %) | <0.001 |
28-day mortalityb | 15 (11 %) | 15 (47 %) | <0.001 |
ICU length of staya | 6.4 ± 11.7 | 1.4 ± 2.1 | 0.017 |
Vasoactive drug useb | 47 (34 %) | 11 (34 %) | 0.99 |
Sedative drug useb | 68 (49 %) | 13 (41 %) | 0.43 |
Opioids useb | 86 (62 %) | 15 (47 %) | 0.16 |
Renal replacement therapyb | 12 (9 %) | 5 (16 %) | 0.32 |
Admission cause | |||
Medicalb | 74 (53 %) | 15 (47 %) | 0.56 |
Elective surgeryb | 49 (35 %) | 9 (28 %) | 0.54 |
Urgent surgeryb | 16 (12 %) | 8 (25 %) | 0.08 |
Mechanically ventilated patients (n = 88) | Mobilized n = 69 | Never mobilized n = 19 | p value |
|---|---|---|---|
Agea | 61 ± 16 | 66 ± 14 | 0.24 |
Maleb | 40 (58 %) | 12 (63 %) | 0.79 |
SOFA scorea | 7 ± 4 | 10 ± 5 | 0.01 |
APACHE II scorea | 19 ± 7 | 25 ± 9 | 0.005 |
Predicted mortality (APACHE II) | 36 % | 60 % | 0.003 |
In-hospital mortalityb | 20 (29 %) | 13 (68 %) | 0.002 |
In ICU mortalityb | 11 (16 %) | 12 (63 %) | <0.001 |
28-day mortalityb | 10 (14 %) | 13 (68 %) | <0.001 |
ICU length of stay (days)a | 10.7 ± 15.5 | 1.7 ± 2.6 | <0.001 |
MV duration (days)a | 4.9 ± 7.7 | 1.3 ± 1.1 | 0.04 |
Vasoactive drug useb | 39 (57 %) | 10 (53 %) | 0.79 |
Sedative drug useb | 58 (84 %) | 13 (68 %) | 0.18 |
Opioids useb | 47 (68 %) | 9 (47 %) | 0.18 |
Renal replacement therapyb | 10 (14 %) | 5 (26 %) | 0.30 |
PaO2/FiO2 ratiob | |||
>300 (n = 11) | 10 (91 %) | 1 (9 %) | 0.44 |
201–300 (mild) (n = 13) | 9 (69 %) | 4 (31 %) | 0.46 |
101–200 (moderate) (n = 42) | 34 (81 %) | 8 (19 %) | 0.61 |
≤100 (severe) (n = 22) | 16 (73 %) | 6 (27 %) | 0.55 |
Non-mechanically ventilated (n = 83) | Mobilized n = 70 | Never mobilized n = 13 | p value |
|---|---|---|---|
Agea | 56 ± 17 | 56 ± 20 | 0.96 |
Maleb | 40 (57 %) | 6 (46 %) | 0.54 |
SOFA scorea | 4 ± 3 | 5 ± 5 | 0.56 |
APACHE II scorea | 15 ± 6 | 16 ± 8 | 0.67 |
Predicted mortality (APACHE II) | 22 % | 19 % | 0.69 |
In-hospital mortalityb | 6 (8 %) | 3 (23 %) | 0.14 |
In ICU mortalityb | 0 (0 %) | 1 (8 %) | 0.15 |
28-day mortalityb | 5 (7 %) | 2 (15 %) | 0.30 |
ICU length of staya | 2.2 ± 1.6 | 0.8 ± 0.5 | <0.001 |
Vasoactive drug useb | 8 (11 %) | 1 (8 %) | 0.99 |
Sedative drug useb | 10 (14 %) | 0 (0 %) | 0.34 |
Opioids useb | 39 (56 %) | 6 (46 %) | 0.55 |
Renal replacement therapyb | 2 (3 %) | 0 (0 %) | 0.99 |
PaO2/FiO2 ratiob | |||
> 300 (n = 37) | 29 (78 %) | 8 (22 %) | 0.22 |
201–300 (mild) (n = 22) | 19 (86 %) | 3 (14 %) | 0.99 |
101–200 (moderate) (n = 16) | 15 (94 %) | 1 (6 %) | 0.44 |
≤100 (severe) (n = 8) | 7 (88 %) | 1 (13 %) | 0.99 |